KalVista Pharmaceuticals, Inc.
DelistedCIK 1348911fmd_0DTH027R3AZKX0FT4FHVS7FJH9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Mar 31, 2026, 57 periods
Latest annual · FY2024
Millions- Total revenues
- 50
- Operating income
- (188)
- Net income
- (183)
- Free cash flow
- (153)
Latest quarter · Q1 FY2026
Millions- Total revenues
- 41
- Gross profit
- 38
- Operating income
- (23)
- Net income
- (23)
- Free cash flow
- (15)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
KalVista Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$188 million | -$140.4 million | 10-K 2025-07-10 · proof | |
| Net income | -$183.4 million | -$126.6 million | 10-K 2025-07-10 · proof | |
| Cash from operating activities | -$152.9 million | -$89.2 million | 10-K 2025-07-10 · proof | |
| Free cash flow | -$153.3 million | -$89.3 million | 10-K 2025-07-10 · proof | |
| Total assets | $56.8 million | $6.6 million | +754.8% | 10-K 2016-03-30 · proof |
| Total liabilities | $7.5 million | $11.3 million | -33.6% | 10-K 2016-03-30 · proof |
| Cash and cash equivalents | $53.7 million | $3.9 million | +1,278.6% | 10-K 2016-03-30 · proof |
- What was KalVista Pharmaceuticals, Inc.'s operating income in fiscal 2025?
- KalVista Pharmaceuticals, Inc. reported operating income of -$188 million for fiscal 2025 (the year ended Apr 30, 2025), against -$140.4 million the year before. Source: the 10-K filed with the SEC on Jul 10, 2025. SEC
- What was KalVista Pharmaceuticals, Inc.'s net income in fiscal 2025?
- KalVista Pharmaceuticals, Inc. reported net income of -$183.4 million for fiscal 2025 (the year ended Apr 30, 2025), against -$126.6 million the year before. Source: the 10-K filed with the SEC on Jul 10, 2025. SEC
- What was KalVista Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2025?
- KalVista Pharmaceuticals, Inc. reported cash from operating activities of -$152.9 million for fiscal 2025 (the year ended Apr 30, 2025), against -$89.2 million the year before. Source: the 10-K filed with the SEC on Jul 10, 2025. SEC
- What was KalVista Pharmaceuticals, Inc.'s free cash flow in fiscal 2025?
- KalVista Pharmaceuticals, Inc. reported free cash flow of -$153.3 million for fiscal 2025 (the year ended Apr 30, 2025), against -$89.3 million the year before. Source: the 10-K filed with the SEC on Jul 10, 2025. SEC
- What are KalVista Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2015, KalVista Pharmaceuticals, Inc. reported total assets of $56.8 million, against $6.6 million a year earlier (+754.8%). Source: the 10-K filed with the SEC on Mar 30, 2016. SEC
- What are KalVista Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2015, KalVista Pharmaceuticals, Inc. reported total liabilities of $7.5 million, against $11.3 million a year earlier (-33.6%). Source: the 10-K filed with the SEC on Mar 30, 2016. SEC
- What are KalVista Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2015, KalVista Pharmaceuticals, Inc. reported cash and cash equivalents of $53.7 million, against $3.9 million a year earlier (+1,278.6%). Source: the 10-K filed with the SEC on Mar 30, 2016. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1348911&period_type=annual&limit=5"Information only, not investment advice.